EP
ACRS icon

Essential Partners’s Aclaris Therapeutics ACRS Stock Holding History

Essential Partners’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$26 Hold
5
– – ﹤0.01% 2820
2026
Q1 		$19 Hold
5
– – ﹤0.01% 2824
2025
Q4 		$15 Buy
+5
New +$13 ﹤0.01% 2732

Other funds holding ACRS

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

Essential Partners's ACRS Position: Q2 2026 in Review

Essential Partners held its Aclaris Therapeutics (ACRS) position steady in Q2 2026 at 5 shares worth $26. The position accounts for ﹤0.01% of the portfolio, ranked #2820.

Essential Partners first reported a position in ACRS in Q4 2025 and has held it in 3 quarters since. 149 funds tracked by Wall St. Rank hold ACRS as of Q2 2026.

  • Essential Partners held 5 shares of Aclaris Therapeutics worth $26 as of Q2 2026.
  • Essential Partners left its Aclaris Therapeutics share count unchanged in Q2 2026.
  • Aclaris Therapeutics made up ﹤0.01% of Essential Partners's portfolio in Q2 2026, its #2820 holding.
  • Essential Partners first reported a position in Aclaris Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 149 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.